Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.12498 http://scihub22266oqcxt.onion/10.1111/bcp.12498 C4415708!4415708!25139610     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25139610.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Clin+Pharmacol 2015 ; 79 (5): 709-19 Nephropedia Template TP {{tp|p=25139610|t=2015. Rituximab in the treatment of autoimmune haemolytic anaemia |pdf=|usr=}}{{25139610}} gab.com Text Rituximab in the treatment of autoimmune haemolytic anaemia JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25139610 #FOAvip Rituximab is a B-cell depleting monoclonal antibody that is gaining popularity as an effective therapy for many autoimmune cytopenias. This article systematically evaluates its therapeutic efficacy in the treatment of different types of autoimmune haemolytic anaemia. We conclude that there is sufficient evidence to recommend it as a second line therapy for warm autoimmune haemolytic anaemia (wAIHA) either as monotherapy or combined therapy. Evidence from a single randomized controlled trial suggests that it may also be more efficacious as first line therapy in combination with steroids than steroids alone. A fewer number of studies have assessed its role in cold autoimmune haemolytic anaemia (cAIHA) and cold agglutinin disease (CAD) with success rates varying from 45?66%. In the absence of alternative definitive therapy, rituximab should be considered for patients with symptomatic CAD and significant haemolysis. Case reports of its efficacy in mixed autoimmune haemolytic anaemias are available but evidence from case series or larger cohorts are nonexistent. Twit Text FOAVip Rituximab in the treatment of autoimmune haemolytic anaemia ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25139610 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25139610 #FOAvip English Wikipedia <ref>{{Cite pmid|25139610}}</ref> Rituximab in the treatment of autoimmune haemolytic anaemia #MMPMID25139610 Rodrigo C; Rajapakse S; Gooneratne L Br J Clin Pharmacol 2015[May]; 79 (5): 709-19 PMID25139610show ga Rituximab is a B-cell depleting monoclonal antibody that is gaining popularity as an effective therapy for many autoimmune cytopenias. This article systematically evaluates its therapeutic efficacy in the treatment of different types of autoimmune haemolytic anaemia. We conclude that there is sufficient evidence to recommend it as a second line therapy for warm autoimmune haemolytic anaemia (wAIHA) either as monotherapy or combined therapy. Evidence from a single randomized controlled trial suggests that it may also be more efficacious as first line therapy in combination with steroids than steroids alone. A fewer number of studies have assessed its role in cold autoimmune haemolytic anaemia (cAIHA) and cold agglutinin disease (CAD) with success rates varying from 45?66%. In the absence of alternative definitive therapy, rituximab should be considered for patients with symptomatic CAD and significant haemolysis. Case reports of its efficacy in mixed autoimmune haemolytic anaemias are available but evidence from case series or larger cohorts are nonexistent. äRituximab in the treatment of autoimmune haemolytic anaemia (epmc).pdf DeepDyve Pubget Overpricing